MyFinsight

HomeBlogAbout

MyFinsight

Making company financials insightful for everyone

  • About
  • Blog
  • Privacy Policy
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

|||

Cash Flow Overview

Change in Cash
$176,684K
Free Cash flow
$549,451K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
    • Proceeds from sale of short-term...
    • Stock-based compensation expense
    • Accounts payable
    • Others
Negative Cash Flow Breakdown
    • Repayment of 0 percent convertib...
    • Purchases of short-term investme...
    • Other current and long-term asse...
    • Others
Cash Flow
2026-06-30
2026-03-31
2025-09-30
2025-06-30
Net loss
-114,646
59,465
-128,606
-23,387
Depreciation
3,433
-3,448
2,255
4,494
Amortization of right-of-use operating lease assets
3,505
-3,318
1,626
5,177
Amortization of other assets
700
-1,140
621
1,180
Amortization of discount on investments, net
3,343
-11,873
5,085
12,978
Amortization of debt issuance costs
1,801
-2,591
1,652
3,288
Non-cash royalty revenue related to sale of royalties
10,698
-26,789
13,584
24,894
Non-cash interest related to sale of future royalties
17,354
-37,780
17,799
37,165
Stock-based compensation expense
45,595
-47,279
31,146
59,408
Loss (gain) on investments, net
-10,182
13,146
29,908
-20,471
Non-cash losses related to other assets
441
3,683
-3,940
297
Escrow deposit for maturity of 0 percent convertible senior notes due april 2026
-
632,511
-
-
Contracts receivable
-14,839
75,205
-27,972
-39,608
Inventories
24,964
-14,938
2,135
12,465
Other current and long-term assets
30,875
-116,099
100,953
22,536
Accounts payable
21,678
26,021
-8,807
-20,309
Income taxes
3
94
20
47
Accrued compensation
14,244
-67,592
10,455
-23,050
Accrued liabilities and other liabilities
-8,152
-66,680
84,148
3,535
Deferred contract revenue
-8,077
29,783
-16,113
-34,488
Net cash provided by (used in) operating activities
565,531
-661,945
-131,437
563
Purchases of short-term investments
320,250
-933,840
323,938
802,657
Proceeds from sale of short-term investments
361,981
-549,927
422,206
880,545
Purchases of property, plant and equipment
16,080
-8,389
5,270
24,882
Acquisition of licenses and other assets, net
2,154
-2,789
1,660
2,615
Net cash provided by investing activities
23,497
395,091
91,338
50,391
Proceeds from issuance of common stock through equity plans, net
20,258
-27,485
81,259
3,528
Proceeds from issuance of common stock in public offering, net
-
-
0
-
Repayment of 0 percent convertible senior notes due 2026
432,511
-
-
-
Principal payments on mortgage debt
41
-79
41
82
Net cash provided by (used in) financing activities
-412,294
-27,406
81,218
3,446
Effects of exchange rates on cash
-50
-883
-82
827
Net increase (decrease) in cash and cash equivalents
176,684
-295,143
41,037
55,227
Cash and cash equivalents at beginning of period
338,341
338,341
242,077
-
Cash and cash equivalents at end of period
350,065
173,381
338,341
-
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.

Time Plot

Show the time plot by selecting a row from the table.

Cash Flow

something is missing$632,511K Proceeds from sale ofshort-term investments$361,981K (-58.89%↓ Y/Y)Stock-based compensationexpense$45,595K (-23.25%↓ Y/Y)Accounts payable$21,678K (206.74%↑ Y/Y)Non-cash interestrelated to sale of future...$17,354K (-53.31%↓ Y/Y)Contracts receivable-$14,839K (62.54%↑ Y/Y)Accrued compensation$14,244K (161.80%↑ Y/Y)Loss (gain) oninvestments, net-$10,182K (50.26%↑ Y/Y)Amortization of right-of-useoperating lease assets$3,505K (-32.30%↓ Y/Y)Depreciation$3,433K (-23.61%↓ Y/Y)Amortization of debt issuancecosts$1,801K (-45.23%↓ Y/Y)Amortization of other assets$700K (-40.68%↓ Y/Y)Non-cash losses relatedto other assets$441K (48.48%↑ Y/Y)Income taxes$3K (-93.62%↓ Y/Y)Net cash provided by(used in) operating...$565,531K (100349.56%↑ Y/Y)Net cash provided byinvesting activities$23,497K (-53.37%↓ Y/Y)Canceled cashflow$200,755K Canceled cashflow$338,484K Net increase(decrease) in cash and cash...$176,684K (219.92%↑ Y/Y)Canceled cashflow$412,344K Net loss-$114,646K (-390.21%↓ Y/Y)Other current andlong-term assets$30,875K (37.00%↑ Y/Y)Inventories$24,964K (100.27%↑ Y/Y)Non-cash royalty revenuerelated to sale of...$10,698K (-57.03%↓ Y/Y)Accrued liabilities andother liabilities-$8,152K (-330.61%↓ Y/Y)Deferred contractrevenue-$8,077K (76.58%↑ Y/Y)Amortization of discount oninvestments, net$3,343K (-74.24%↓ Y/Y)Proceeds from issuance ofcommon stock through...$20,258K (474.21%↑ Y/Y)Purchases of short-terminvestments$320,250K (-60.10%↓ Y/Y)Purchases of property,plant and equipment$16,080K (-35.37%↓ Y/Y)Acquisition of licenses andother assets, net$2,154K (-17.63%↓ Y/Y)Net cash provided by(used in) financing...-$412,294K (-12064.42%↓ Y/Y)Effects of exchangerates on cash-$50K (-106.05%↓ Y/Y)Canceled cashflow$20,258K Repayment of 0 percentconvertible senior notes due...$432,511K Principal payments onmortgage debt$41K (-50.00%↓ Y/Y)

IONIS PHARMACEUTICALS INC (IONS)

IONIS PHARMACEUTICALS INC (IONS)